Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Lenvatinib + Chemotherapy in Malignant Pleural Mesothelioma
NCT06318286Phase 2Active, not recruiting
- Sponsor
- Hyogo Medical University
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in malignant pleural mesothelioma (MPM), sponsored by Hyogo Medical University. Started Mar 2024; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT06318286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318286.